>>South San Francisco, CA, January 3, 2005 - Theravance, Inc. (NASDAQ: THRX) announced today that it has enrolled the first subjects in a Phase 1 clinical study designed to assess the safety, tolerability and pharmacokinetics of its investigational gastrointestinal (GI) prokinetic, TD-2749.
TD-2749 is a selective 5-HT4 agonist discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for GI motility disorders such as chronic constipation, constipation-predominant irritable bowel syndrome (C-IBS), opioid-induced constipation, functional dyspepsia and diabetic gastroparesis.
"GI disorders potentially amenable to prokinetic treatment are common", said Michael Kitt, MD, Senior Vice President of Development at Theravance, "The goal for our program is to develop a once-a-day oral medicine that is more effective than the market leading medicines."
Dr. Patrick P. A. Humphrey, Executive Vice President of Research at Theravance, said, "We believe that our multivalent approach to drug discovery has the potential to provide a superior next-generation medicine to treat GI motility disorders. TD-2749 is the fifth drug discovered at Theravance to enter into human clinical testing in the last four years. In 2001, telavancin, an investigational antibiotic for the treatment of serious Gram-positive infections, entered into human clinical studies and is currently in Phase 3. In 2002, the lead compound in our long-acting beta2 agonist collaboration with GSK entered the clinic, followed by our second compound in that program in 2004. Our overactive bladder program initiated Phase 1 studies in 2003 and now our GI prokinetic is being tested in human volunteers." <<
snip
Cheers, Tuck |
